Bora Pharmaceuticals [TWO: 6472]
6472]

The phenomenal rise in the price of medicines and the need for manufacturers to shrink their base of contacts while maintaining their global reach and access to technologies have made CMOs the lynchpin to pharmaceutical companies. In today’s fast-paced world, CMOs give pharmaceutical and biologic manufacturers one of the most important assets–time. However, while employing a CMO, both parties need to be aware of compliance liabilities attached to the products in question. Compliance of the CMO needs to be monitored by the contractor while also assisting with the deployment of risk prevention action plans.

So, how does one choose the perfect CMO?

Quality with flexibility coupled with overall transparency and a clear vision of strategy in the communication process–attributes that form the core of Bora Pharmaceuticals. A leader in the manufacturing and selling of generic, brand, and over-thecounter (OTC) drugs to the world, Bora Pharmaceuticals insists on reliability and efficiency without any compromises and covers the entire pharmaceutical supply chain from research and development to sales and distribution.

Bora Pharmaceuticals is a premier international CGMP CDMO specializing in complex oral solid dosage (tablet & capsules), liquids (solutions, suspensions, & nasal sprays), and semi-solids (creams & gels) pharmaceutical Rx and OTC products for late-phase Clinical through Commercial manufacturing and packaging. Bora Pharmaceuticals owns and operates three state-of-theart CGMP manufacturing facilities (Taiwan and Canada) built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. The company can handle high potency compounds, solvents, flammables, and IR/SR/ER release profile products.

We see a growing demand for large-scale, customer-centric contract manufacturers–not only in the growing biologics space, but also in the persistent pipeline of novel oral solid drug products

What makes Bora Pharmaceuticals unique in semi-solids and liquids is its ability to manufacture from clinical to commercial scales with high throughput and the ability to handle solvents. Offering a comprehensive predominantly focuses on the CDMO, prescription drugs, and consumer healthcare, and OTC space. In essence, Bora Pharmaceuticals partners with leading pharmaceutical companies to enable the development, manufacture, and packaging of complex modified release oral dosage drug products. To that end, its R&D laboratory has created a rich and diverse product pipeline with global licensing potential. In fact, the Taiwan-based firm has a robust regulatory record, achieving USFDA, MHRA, TFDA, and PIC/S certifications.

With over 25 percent of its team devoted to quality, Bora can guarantee all projects are delivered to the highest standards. “Contributing to Better Health All Over the World” is Bora’s Mission. The management teams have a People First mindset when making decisions. Bora Group is motivated to invest in R&D, CDMO service, marketing, and global strategic layout in delivering and facilitating health care and medicines that are made by Bora. “

We’re currently the largest CDMO in Taiwan, offering contract development and manufacturing services for complex oral solid dosage (OSD) drug products,” says Bobby Sheng, CEO and Chairman, Bora Pharmaceuticals. “We currently produce 12 percent of all drug products exported from Taiwan, but our ambitions are far more global still. We see a growing demand for large-scale, customer-centric contract manufacturers–not only in the growing biologics space, but also in the persistent pipeline of novel oral solid drug products,” concludes Sheng.